Skip to main content

Gout

Dr. John Cush
@RheumNow
Colchicine & Statins: A significant interaction? Colchicine is frequently used in rheumatologic practice. Current ACR guidelines for gout management support anti-inflammatory prophylaxis, including colchicine, during initiation and uptitration of urate-lowering therapy https://t.co/eyDbfpQajN

Colchicine & Statins: A significant interaction?

Brian Jaros, MD

Aside from diarrhea, colchicine use is generally well tolerated, but its metabolism via the CYP3A4 cytochrome P450 enzyme pathway poses a potential risk of medication interaction. Statins are one of the most widely prescribed medication classes also metabolized by this pathway thus positing

Dr. John Cush
@RheumNow
? value of FamHx in Rheum evals? My bias is that few Dz are heritable - #Ank Spondylitis, #gout, DIP Osteoarthritis! But literature says there's high heritability for SLE, RA, systemic sclerosis, Sjögren's, & autoimmune endocrinopathies. WHAT do you think? https://t.co/WGyQqpY1qX
Dr. John Cush
@RheumNow
Italian retrospective study of 36 difficult #GCA pts (89% relapsed; 72% prev TCZ) showed Clinical remission 85%, 81%, & 83% at 3, 6, & 12 mos. GC-free remission increased to 15%, 28%, & 40% at 3, 6, & 12 mos. GCs d/c in 43%. Results at odds w/ ph III GCAptAIN RCT where SEC https://t.co/VnMSCPwMrn

Don’t Hold the JAK (10.9.2026)

Jack Cush, MD

On this week's podcast, Dr. Jack Cush reviews the news: Steroids are easy to start and hard to stop; hold the MTX but not the biologic or JAK, weighing in on avacopan, and age-old messages for old-age patients. 

Dr. John Cush
@RheumNow
The Friday RheumNow podcast has dropped! In this week's episode, "Rheumatology Pay Up," Dr. Jack Cush covers: • Rheumatology physician pay rose 10.4% year-over-year • New data on colchicine and tofacitinib in knee OA • What a new study tells us about earlier axSpA diagnosis https://t.co/oXsNruWnc2
Dr. John Cush
@RheumNow
It’s almost time. 🔥 Registration for RheumNow Live 2027 opens OCTOBER 1. Two days of practical, engaging rheumatology education designed to challenge how you think and influence how you practice. 📅 Jan 30–31, 2027 📍 Dallas + Online https://t.co/Ju0zzYX8Tl
Dr. John Cush
@RheumNow
Korean National Health Insurance claims study of 4,107 newly Dx gout on allopurinol x 24 mos (vs non-gout controls). Gout significantly higher risk of fractures (aHR 5.52_; 95% CI 4.19–7.26), highest in those with low-adherence to allopurinol (aHR 5.91). Consistent trends seen https://t.co/cTO4lGtYAy
×